GlaxoSmithKline Pharmaceuticals Limited has announced the outcome of its Board of Directors’ meeting held on November 3, 2026. The board approved the Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended September 30, 2026. Additionally, the company announced the appointment of M/s Walker Chandiok & Co LLP as its new Statutory Auditors for a five-year term, commencing from the financial year 2027-28. Mr. Sandeep Seth was also appointed as Head – Ethics & Compliance.
Board Meeting Outcomes
GlaxoSmithKline Pharmaceuticals Limited held a Board of Directors meeting on November 3, 2026. During this meeting, the board transacted several key businesses, including the approval of the company’s financial results and changes in senior management and statutory auditors.
Financial Results Approved
The Board approved the Un-audited Standalone and Consolidated Financial Results for the second quarter and half year ended September 30, 2026. These results, along with the Limited Review Report of the Auditors, have been submitted to the stock exchanges.
Changes in Senior Management
In line with the SEBI Listing Regulations, the company informed that Mr. Sandeep Seth has been appointed as the Head – Ethics & Compliance, effective from November 3, 2026. Mr. Seth brings over 20 years of experience in ethics, compliance, and governance across various sectors.
New Statutory Auditors Appointed
Following a recommendation from the Audit Committee, the Board approved the appointment of M/s Walker Chandiok & Co LLP, Chartered Accountants, as the company’s Statutory Auditors. This appointment is for a first term of five consecutive years, commencing from the financial year 2027-28 and concluding at the 107th Annual General Meeting in respect of the financial year 2031-32. This appointment is subject to the approval of the Members at the upcoming Annual General Meeting.
Financial Highlights (Standalone)
For the quarter ended September 30, 2026, the standalone revenue from operations was ₹117,991 Lakhs, with a total income of ₹125,268 Lakhs. The profit for the period stood at ₹33,462 Lakhs.
Financial Highlights (Consolidated)
On a consolidated basis, for the quarter ended September 30, 2026, the revenue from operations was ₹118,357 Lakhs, and the total income was ₹125,635 Lakhs. The consolidated profit for the period was ₹33,588 Lakhs.
Meeting Details
The Board of Directors’ meeting commenced at 3:45 p.m. and concluded at 6:00 p.m. on November 3, 2026.
Source: BSE
